Results 161 to 170 of about 2,123,606 (402)

Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma

Journal of experimental & clinical cancer research : CR, 2019
Molecular targeted therapy for advanced hepatocellular carcinoma (HCC) has changed markedly. Although sorafenib was used in clinical practice as the first molecular targeted agent in 2007, the SHARPE and Asian-Pacific trials demonstrated that sorafenib ...
Ziyu Liu, Yan Lin, Jinyan Zhang, Yumei Zhang, Yong-Qiang Li, Zhi-Hui Liu, Qian Li, Ming Luo, R. Liang, J. Ye   +9 more
semanticscholar   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Drug delivery in overcoming the blood-brain barrier: role of nasal mucosal grafting [PDF]

, 2017
The blood–brain barrier (BBB) plays a fundamental role in protecting and maintaining the homeostasis of the brain. For this reason, drug delivery to the brain is much more difficult than that to other compartments of the body. In order to bypass or cross
Carafa, Maria, Di Marzio, Luisa, Hanieh, PATRIZIA NADIA, Marianecci, Carlotta, Paolino, Donatella, Rinaldi, Federica   +5 more
core   +1 more source

Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future Directions.

Biological and Pharmaceutical Bulletin, 2015
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most lethal neoplasm, causing an estimated 700000 deaths annually. Currently HCC has only one systemic molecular targeted therapy, the multi-kinase inhibitor, sorafenib.
Kyung-Ju Choi, I. Baik, S. Ye, Yun-Han Lee   +3 more
semanticscholar   +1 more source

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy [PDF]

, 2010
In recent years, tyrosine kinases (TKs) have been recognized as central players and regulators of cancer cell proliferation, apoptosis, and angiogenesis, and are therefore considered suitable potential targets for anti-cancer therapies.
J Rafael Sierra, Silvia Giordano, Virna Cepero   +2 more
core   +2 more sources

Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy

OncoTarget, 2015
Melanoma is currently divided on a genetic level according to mutational status. However, this classification does not optimally predict prognosis. In prior studies, we have defined gene expression phenotypes (high-immune, pigmentation, proliferative and
Helena Cirenajwis, Henrik Ekedahl, M. Lauss, K. Harbst, A. Carneiro, J. Enoksson, Frida Rosengren, L. Werner-Hartman, Therese Törngren, A. Kvist, E. Fredlund, P. Bendahl, K. Jirström, L. Lundgren, J. Howlin, Å. Borg, Sofia K Gruvberger-Saal, L. Saal, K. Nielsen, M. Ringnér, H. Tsao, H. Olsson, C. Ingvar, J. Staaf, G. Jönsson   +24 more
semanticscholar   +1 more source

KRAS and GNAS mutations in cell‐free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms—an observational pilot study

Molecular Oncology, EarlyView.
This study demonstrates that KRAS and GNAS mutations are more prevalent in patients with resected intraductal papillary mucinous neoplasms (IPMN) compared to those under clinical surveillance. GNAS mutations significantly differ between the two patient cohorts, indicating that their absence may serve as a potential biomarker to support conservative ...
Christine Nitschke, Marie Tölle, Philipp Walter, Kira Meißner, Mara Goetz, Jolanthe Kropidlowski, Andreas W. Berger, Jakob R. Izbicki, Felix Nickel, Thilo Hackert, Klaus Pantel, Harriet Wikman, Faik G. Uzunoglu   +12 more
wiley   +1 more source

Present Molecular Limitations of ON-Bipolar Cell Targeted Gene Therapy [PDF]

, 2017
Recent studies have demonstrated the safety and efficacy of ocular gene therapy based on adeno-associated viral vectors (AAVs). Accordingly, a surge in promising new gene therapies is entering clinical trials, including the first optogenetic therapy for ...
Andreas Ebneter, Elmar C. Hulliger, Lara Girod, Michiel van Wyk, Sonja Kleinlogel   +4 more
core   +1 more source

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

Journal of Clinical Oncology, 2018
Purpose Detection of specific molecular alterations in tumors guides the selection of effective targeted treatment of patients with several types of cancer.
J. Hainsworth, F. Meric-Bernstam, C. Swanton, H. Hurwitz, D. Spigel, C. Sweeney, H. Burris, R. Bose, B. Yoo, A. Stein, M. Beattie, R. Kurzrock   +11 more
semanticscholar   +1 more source